[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-360545-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-360545-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","pharmacological-targeting-of-sf3a1-mdm4-splicing-vulnerability-in-ovarian-cancer-with-rifaximin-and-antisense-oligonucleotide","Pharmacological targeting of SF3a1-MDM4 splicing vulnerability in ovarian cancer - with rifaximin and antisense oligonucleotide","","Ovarian cancer remains a lethal gynecological malignancy with limited mechanistic clarity and insufficient targeted options. This study examines how SF3a1 regulates an essential alternative splicing vulnerability involving MDM4, influencing cancer cell survival pathways. Bioinformatics and experimental gain- and loss-of-function approaches define SF3a1-dependent splicing changes, including MDM4-short isoform degradation. Antisense oligonucleotide targeting of the SF3a1-binding sequence and pharmacologic SF3a1 inhibition with rifaximin suppress tumor proliferation and enhance cisplatin efficacy, while CDK6-mediated SF3a1 phosphorylation modulates this axis.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/pharmacological-targeting-of-sf3a1-mdm4-splicing-vulnerability-in-ovarian-cancer-with-rifaximin-and-antisense-oligonucleotide/360545/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/pharmacological-targeting-of-sf3a1-mdm4-splicing-vulnerability-in-ovarian-cancer-with-rifaximin-and-antisense-oligonucleotide/360545.png","ImageObject",300,407,{"name":42,"@type":43},"McGucket","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What role does SF3a1 play in ovarian cancer according to the study?","Question",{"text":63,"@type":64},"SF3a1 is reported to be indispensable for ovarian cancer pathogenesis. SF3a1 knockdown impairs malignant behaviors and reprograms the ovarian cancer splicing landscape, including effects on MDM4 isoform production and degradation.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does MDM4 splicing contribute to SF3a1-driven ovarian cancer inhibition?",{"text":68,"@type":64},"The study shows that a skipped exon event in MDM4 increases the formation of the MDM4-short isoform, which is subsequently degraded. Reduced total MDM4 level activates the P53 pathway, inhibiting ovarian cancer.",{"name":70,"@type":61,"acceptedAnswer":71},"How are rifaximin and antisense oligonucleotide used for therapeutic targeting?",{"text":72,"@type":64},"A targeted antisense oligonucleotide binds the SF3a1-associated MDM4 pre-mRNA sequence to mimic SF3a1 knockdown effects and inhibit proliferation. Rifaximin, identified as an inhibitor of SF3a1, effectively kills ovarian cancer cells and improves cisplatin efficacy in combination therapy.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},360545,1791164482,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},1236954412713,"https://us-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Shuai et al. Journal of Translational Medicine (2026) 24:768  \n[https://doi.org/10.1186/s12967-026-08182-2](https://doi.org/10.1186/s12967-026-08182-2)  \nJournal of Translational Medicine  \nRESEARCH Open Access  \nPharmacological targeting of SF3a1-MDM4  splicing vulnerability in ovarian cancer  \nwith rifaximin and antisense oligonucleotide  \nXueqian Shuai1,2, Yaoqi Sun3, Jiale Li4, Yuan Gao5*, Zhongping Cheng1,6* and Shupeng Liu2*  \nAbstract  \nBackground Ovarian cancer (OC) is the most deadly gynecological malignancy, mainly due to insufficient studies on its mechanisms and lack of effective therapies. Alternative splicing (AS) dysregulation has deepened understanding of cancer pathogenesis. As a constitutive molecular consisting spliceosome, the pathogenesis and therapeutic potential of SF3a1 in solid tumors are rarely studied.  \nMethods The expressions and prognostic values of SF3a1 were accessed using bioinformatics. The functions of SF3a1 were evaluated using gain-and loss-of-function strategies. Whole transcriptome sequencing and mass spectrometry analysis were conducted to capture signaling axis of SF3a1 . Semi-qPCR, qRT–PCR, WB, IHC and rescue experiments were exploited to validate the sequencing results. Targeted antisense oligonucleotide (ASO) was designed and its treatment efficacy was verified. Virtual screening was used to identify small molecule inhibitor of SF3a1, whose therapeutic potential on OC was evaluated via in vitro and in vivo assays.  \nResults This study found SF3a1 played an indispensable role in OC pathogenesis. SF3a1 knockdown impaired malignant behaviors and reprogrammed splicing landscape of OC cells. Skipped exon (SE) event of MDM4-exon6 (exon7 in mouse) increased, leading to formation of MDM4-short (MDM4-s) isoform, which was subsequently degraded. Total MDM4 level was therefore downregulated, leading to P53 pathway activation and OC inhibition. Additionally, ASO targeting MDM4 pre-mRNA sequence bound by SF3a1 mimicked the alternative regulation caused by SF3a1 knockdown, and showed significant inhibitory effect on OC proliferation. Rifaximin, identified as an inhibitor targeting SF3a1, effectively killed OC cells and enhanced cisplatin’s efficacy in combination therapy. Moreover, CDK6 was found to phosphorylate SF3a1 at S359, which decreased its protein half-life and influenced downstream MDM4 splicing.  \nConclusions Our findings uncover the oncogenic impact of SF3a1 in OC and highlight the prospects to target it by rifaximin and downstream MDM4 AS by ASO, synergistically improving the therapeutic effectiveness of cisplatin in OC.  \n*Correspondence:  \nYuan Gao [gaoyuan_324@aliyun.com](gaoyuan_324@aliyun.com)[ ](gaoyuan_324@aliyun.com)Zhongping Cheng [czpwp129@rjh.com.cn](czpwp129@rjh.com.cn)[ ](czpwp129@rjh.com.cn)Shupeng Liu [lshup@tongji.edu.cn](lshup@tongji.edu.cn)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.o","cbCaigkvtTUx0PnF","https://ap.wps.com/l/cbCaigkvtTUx0PnF","pdf",8746584,21,"English","# Abstract\n# Background\n# Methods\n# Results\n# Conclusions\n# Keywords","[{\"question\":\"What role does SF3a1 play in ovarian cancer according to the study?\",\"answer\":\"SF3a1 is reported to be indispensable for ovarian cancer pathogenesis. SF3a1 knockdown impairs malignant behaviors and reprograms the ovarian cancer splicing landscape, including effects on MDM4 isoform production and degradation.\"},{\"question\":\"How does MDM4 splicing contribute to SF3a1-driven ovarian cancer inhibition?\",\"answer\":\"The study shows that a skipped exon event in MDM4 increases the formation of the MDM4-short isoform, which is subsequently degraded. Reduced total MDM4 level activates the P53 pathway, inhibiting ovarian cancer.\"},{\"question\":\"How are rifaximin and antisense oligonucleotide used for therapeutic targeting?\",\"answer\":\"A targeted antisense oligonucleotide binds the SF3a1-associated MDM4 pre-mRNA sequence to mimic SF3a1 knockdown effects and inhibit proliferation. Rifaximin, identified as an inhibitor of SF3a1, effectively kills ovarian cancer cells and improves cisplatin efficacy in combination therapy.\"}]","Pharmacological targeting of SF3a1-MDM4 splicing vulnerability in ovarian cancer - with rifaximin and antisense oligonucleotide | PDF",1790140485,53,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fdb0ee54d7310e71c978ded2974c3150.webp",983,1310,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c61e7281ae5c76814b305a201a6c8e16.webp",982,1309,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/12ca8c142df4f537519269f5fab02d8c.webp",981,1308,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8158d4c8288f586bc7869fc206a90963.webp",980,1306]